Network-Based Computational Identification of Bioactive Compound Combinations for Personalized Cancer Therapy
Keywords:
network pharmacology; drug synergy; personalized oncology; target modules; robust optimization; multi-omics integrationAbstract
Personalized cancer therapy must select compound combinations that act on the specific dysregulated modules of a tumor while limiting collateral network perturbation. The combinatorial space of bioactive compounds is too large for exhaustive experimental testing, and pair-level synergy models often ignore patient-specific network context, target redundancy, and annotation uncertainty. This manuscript develops a network-based computational framework for identifying and ranking compound combinations for individual tumors. The framework constructs a patient-specific multilayer interaction network, infers dysregulated target modules, maps compounds to protein targets and transcriptional effects, and scores a pair by its excess perturbation of a tumor module beyond an independence reference. A selectivity term penalizes combinations whose targets lie close to essential or healthy-tissue modules, and a robust objective accounts for edge-weight and target-annotation uncertainty. Candidate combinations are ranked under interpretability and safety constraints, producing a reproducible decision rule rather than a single unqualified score. The analytical assessment clarifies when network-community structure improves combination discovery, how mechanistic plausibility differs from statistical association, and which failure modes arise from incomplete interactomes, off-target annotations, and confounding between proliferation and drug response. The framework is intended as a transparent hypothesis-generation and prioritization layer that connects multi-omics evidence, compound-target resources, and pathway-level reasoning. Its practical value lies in narrowing experimental search spaces, exposing assumptions, and producing auditable combination rankings for translational evaluation.
References
1. Barabási, A.-L., & Oltvai, Z. N. (2004). Network biology: Understanding the cell's functional organization. Nature Reviews Genetics, 5(2), 101–113. https://doi.org/10.1038/nrg1272
2. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690. https://doi.org/10.1038/nchembio.118
3. Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007). Drug-target network. Nature Biotechnology, 25(10), 1119–1126. https://doi.org/10.1038/nbt1338
4. Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013). Structure and dynamics of molecular networks: A novel paradigm of drug discovery. Pharmacology & Therapeutics, 138(3), 333–408. https://doi.org/10.1016/j.pharmthera.2013.01.016
5. Chou, T.-C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews, 58(3), 621–681. https://doi.org/10.1124/pr.58.3.10
6. Loewe, S. (1953). The problem of synergism and antagonism of combined drugs. Arzneimittel-Forschung, 3(6), 285–290.
7. Al-Lazikani, B., Banerji, U., & Workman, P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 30(7), 679–692. https://doi.org/10.1038/nbt.2284
8. Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13(10), 714–726. https://doi.org/10.1038/nrc3599
9. Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 45(10), 1113–1120. https://doi.org/10.1038/ng.2764
10. Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., ... Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1074–D1082. https://doi.org/10.1093/nar/gkx1037
11. Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., & von Mering, C. (2019). STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research, 47(D1), D607–D613. https://doi.org/10.1093/nar/gky1131
12. Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., Lahr, D. L., Hirschman, J. E., Liu, Z., Donahue, M., Julian, B., Khan, M., Wadden, D., Smith, I. C., Lam, D., ... Golub, T. R. (2017). A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell, 171(6), 1437–1452.e17. https://doi.org/10.1016/j.cell.2017.10.049
13. Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/10.1002/jcc.21334
14. HerbSyner_Finder: a network community-based model for identifying synergistic combinations from herbal medicines and complex systems. Targetome. 2026;2(2):0-0. doi: 10.48130/targetome-0026-001
15. Cheng, F., Kovács, I. A., & Barabási, A.-L. (2019). Network-based prediction of drug combinations. Nature Communications, 10, 1197. https://doi.org/10.1038/s41467-019-09186-x
16. Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2018). DeepSynergy: Predicting anti-cancer drug synergy with deep learning. Bioinformatics, 34(9), 1538–1546. https://doi.org/10.1093/bioinformatics/btx806
17. Costello, J. C., Heiser, L. M., Georgii, E., Gönen, M., Menden, M. P., Wang, N. J., Bansal, M., Ammad-ud-din, M., Hintsanen, P., Khan, S. A., Mpindi, J.-P., Kallioniemi, O., Honkela, A., Aittokallio, T., Wennerberg, K., Collins, J. J., Gallahan, D., Singer, D., Saez-Rodriguez, J., ... Stolovitzky, G. (2014). A community effort to assess and improve drug sensitivity prediction algorithms. Nature Biotechnology, 32(12), 1202–1212. https://doi.org/10.1038/nbt.2877
18. Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., van der Meer, D., Yang, W., Beck, A., Moudgil, V., Hotta, T., Silva, D., Beck, A., ... Garnett, M. J. (2022). Effective drug combinations in breast, colon and pancreatic cancer cells. Nature, 603(7899), 166–173. https://doi.org/10.1038/s41586-022-04437-2
19. O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., Arthur, W., Cristescu, R., Haines, B. B., Winter, C., Zhang, T., Bloecher, A., & Stover, D. (2016). An unbiased oncology compound screen to identify novel combination strategies. Molecular Cancer Therapeutics, 15(6), 1155–1162. https://doi.org/10.1158/1535-7163.MCT-15-0843
20. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Bioinformatics Insights and Analytics

This work is licensed under a Creative Commons Attribution 4.0 International License.